Full Fed. Circ. Won't Consider Standing In Novartis Drug Case
The full Federal Circuit on Thursday declined to review a three-judge panel's April opinion finding that Argentum Pharmaceuticals lacked standing to appeal a Patent Trial and Appeal Board decision upholding the...To view the full article, register now.
Already a subscriber? Click here to view full article